Study of SB-683699 compared to placebo in subjects with relapsing-remitting multiple sclerosis (MS)

Title
Study of SB-683699 compared to placebo in subjects with relapsing-remitting multiple sclerosis (MS)

Type of intervention
Drug

Form of MS
Relapsing-remitting

Brief summary
SB-683699 is an oral medication that is thought to reduce the number of active white blood cells entering the brain; these white blood cells are part of the disease process for MS. This study will look at whether different doses of SB-683699 are effective and safe in patients with relapsing remitting MS.

Inclusion criteria

Anticipated start date

Recruitment status
This trial has been completed

Recruitment contacts

Further details
http://clinicaltrials.gov/ct2/show/NCT00395317?term=multiple+sclerosis&recr=Open&cntry1=PA%3AAU&rank=1

Region
VIC, NSW, SA, NZ

Trial results
Not yet available

Last updated: April 2012